© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 6, 436-446,
March 21, 2001
© 2001 Oxford University Press
Selective In Vivo and In Vitro Effects of a Small Molecule Inhibitor of Cyclin-Dependent Kinase 4
Affiliations of authors: R. Soni, T. O'Reilly, P. Furet, L. Muller, C. Stephan, S. Zumstein-Mecker, H. Fretz, D. Fabbro, Oncology Research, Novartis Pharma AG, Basel, Switzerland; B. Chaudhuri, Leicester School of Pharmacy, De Montfort University, U.K.
Correspondence to: Professor Bhabatosh Chaudhuri, Leicester School of Pharmacy, De Montfort University, The Gateway, Leicester LE1 9BH, U.K. (bchaudhuri{at}dmu.ac.uk).
Background: Cyclin-dependent kinase 4 (Cdk4) represents a prime target for the treatment of cancer because most human cancers are characterized by overexpression of its activating partner cyclin D1, loss of the natural Cdk4-specific inhibitor p16, or mutation(s) in Cdk4's catalytic subunit. All of these can cause deregulated cell growth, resulting in tumor formation. We sought to identify a small molecule that could inhibit the kinase activity of Cdk4 in vitro and to then ascertain the effects of that inhibitor on cell growth and tumor volume in vivo. Methods: A triaminopyrimidine derivative, CINK4 (a chemical inhibitor of Cdk4), was identified by screening for compounds that could inhibit Cdk4 enzyme activity in vitro. Kinase assays were performed on diverse human Cdks and on other kinases that were expressed in and purified from insect cells to determine the specificity of CINK4. Cell cycle effects of CINK4 on tumor and normal cells were studied by flow cytometry, and changes in phosphorylation of the retinoblastoma protein (pRb), a substrate of Cdk4, were determined by western blotting. The effect of the inhibitor on tumor growth in vivo was studied by use of tumors established through xenografts of HCT116 colon carcinoma cells in mice. Statistical tests were two-sided. Results: CINK4 specifically inhibited Cdk4/cyclin D1 in vitro. It caused growth arrest in tumor cells and in normal cells and prevented pRb phosphorylation. CINK4 treatment resulted in statistically significantly (P = .031) smaller mean tumor volumes in a mouse xenograft model. Conclusions: Like p16, the natural inhibitor of Cdk4, CINK4 inhibits Cdk4 activity in vitro and slows tumor growth in vivo. The specificity of CINK4 for Cdk4 raises the possibility that this small molecule or one with a similar structure could have therapeutic value.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. I. Shapiro Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Fry, P. J. Harvey, P. R. Keller, W. L. Elliott, M. Meade, E. Trachet, M. Albassam, X. Zheng, W. R. Leopold, N. K. Pryer, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Mol. Cancer Ther., November 1, 2004; 3(11): 1427 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zou, D. Ray, A. Aziyu, K. Christov, A. D. Boiko, A. V. Gudkov, and H. Kiyokawa Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence Genes & Dev., November 15, 2002; 16(22): 2923 - 2934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Musgrove, L.-J. K. Hunter, C. S. L. Lee, A. Swarbrick, R. Hui, and R. L. Sutherland Cyclin D1 Overexpression Induces Progestin Resistance in T-47D Breast Cancer Cells Despite p27Kip1 Association with Cyclin E-Cdk2 J. Biol. Chem., December 7, 2001; 276(50): 47675 - 47683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kubo and F. J. Kaye Searching for Selective Cyclin-Dependent Kinase Inhibitors to Target the Retinoblastoma/p16 Cancer Gene Pathway J Natl Cancer Inst, March 21, 2001; 93(6): 415 - 417. [Full Text] [PDF]
|
|